Celanese Discusses Innovative Uses for EVA Polymers at AAPS
EVA applications expanded into oral dosage
DALLAS (October 30, 2014) – Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will be discussing novel applications in pharmaceuticals and medical devices for ethylene vinyl acetate (EVA) polymers during AAPS 2014 in San Diego, California.
At the AAPS annual meeting and expo, Celanese will meet with leaders in the pharmaceutical and medical industries to discuss potential uses of EVA in two ways: as controlled release of drugs for oral administration, and EVA as a foamed excipient to deliver stem cells, growth factors and biologics.
“EVA polymers have a successful history in the pharmaceutical industry as a parenteral controlled release excipient,” said Don Loveday, healthcare and life sciences leader for Celanese. “We believe these two routes of administration offer incredible potential to the medical world.”
EVA in oral applications
The Celanese whitepaper entitled Potential Use of Ethylene Vinyl Acetate Copolymer Excipients in Oral Controlled Release Applications: A Literature Review summarizes the recent developments of EVA-based oral controlled release drug delivery systems. Fifty separate references are cited in this comprehensive paper.
Source: Celanese